John Pavey holds a BA (Hons) in Chemistry from the University of Oxford, a PhD in Organic Chemistry from the University of Liverpool, and completed his postdoctoral research at the University of Cambridge. He brings over two decades of global experience in CMC and chemical development, with a strong track record of advancing API programs from early discovery through regulatory approvals and commercial supply. He has held senior leadership roles at large pharma companies, with experience across modalities including oligonucleotides, antibody-drug conjugates (ADCs), and peptides. His expertise also spans digital chemistry, sustainable manufacturing, and Quality by Design (QbD). He is recognized for building high-performing teams and advancing innovation through collaboration with partners across industry, academia, and regulatory bodies.
